AIDS 2010 - Vienna 18-23 July 2010 - XVIII International AIDS Conference

Viral Hepatitis Co-Infection	WEPDB2

Type:

Oral Poster Discussion

Back

Location:

MR 10

Schedule:

13:00 - 14:00, 21.07.2010

Code:

WEPDB2

Chair:

Cristina Tural, Spain

Presentations in this session:

13:00
WEPDB201
Abstract Phase IV, open label study to evaluate peginterferon alpha-2a plus ribavirin for treatment of chronic hepatitis C in HIV-infected patients with persistently normal alanine aminotransferase
Presented by Miguel Angel von Wichmann de Miguel, Spain
M.A. von Wichmann de Miguel¹, M. Santín², J. Gónzalez³, K. Aguirrebengoa⁴, I. Santos⁵, M. Roget⁶, J. Mallolas⁷, S. Reus⁸, J. Cadafalls⁹, F. Rodríguez¹⁰, CONTRA
¹Hospital de Donostia, San Sebastián, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital La Paz, Madrid, Spain, ⁴Hospital de Cruces, Bilbao, Spain, ⁵Hospital La Princesa, Madrid, Spain, ⁶Consorci Sanitari de Terrasa, Terrasa, Spain, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸Hospital General Universitario de Alicante, Alicante, Spain, ⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Joan XXIII, Tarragona, Spain

13:05
WEPDB202
Abstract Evaluation of risk for esophageal varices by transient elastometry in patients with HIV and HCV infection and liver cirrhosis
Presented by Patrick Ingiliz, Germany
M.K. Mausolf¹, M. Berger¹, J. Breitkreutz¹, J. Hartikainen¹, U. Joppek¹, H. Schulbin¹, H. Stocker¹, C. Traeder¹, C. Weber¹, T. Weipert¹, K. Arastéh¹, R. Weiss², P. Ingiliz¹
¹Vivantes Auguste-Viktoria-Klinikum Berlin, Gastroenterology and Infectious Diseases, Berlin, Germany, ²Hematology and Infectious Diseases, Bremen, Germany

13:10
WEPDB203
Abstract HCV genotypes distribution in the Krasnoyarsk region HIV-positive and HIV-negative populations
Presented by Tatiana Chaychuk, Russian Federation
T. Chaychuk¹, N. Gankina¹, O. Rumyanceva², 1) HCV/HIV-co-infected patients and 2) HCV-infected patients without HIV co-infection
¹Regional Center of AIDS Prevention, Medical Treatment Department, Krasnoyarsk, Russian Federation, ²Regional Center of AIDS Prevention, Laboratory of PCR Diagnostic, Krasnoyarsk, Russian Federation

13:15
WEPDB204
Abstract HBV related complications in HIV positive patients during HAART therapy
Presented by Irina Magdalena Dumitru, Romania
I.M. Dumitru¹, E. Dumitru¹, S. Rugina¹, R.C. Cernat², S. Diaconu²
¹Ovidius University Constanta, Faculty of Medicine, Constanta, Romania, ²Clinical Infectious Diseases Hospital, Constanta, Romania

13:20
WEPDB205
Abstract Hepatitis B virus (HBV) prevalence in the outpatient adult HIV population at the Botswana-Baylor Children's Clinical Centre of Excellence (BBCCCOE) in Gaborone, Botswana
Presented by Premal Patel, Botswana
S. Davis^1,2, P. Patel^1,2, M. Tolle^1,2, V. Mabikwa¹, G. Anabwani^1,2
¹Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana, ²Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children's Hospital, Houston, United States

13:25
WEPDB206
Abstract Late and low compliance with hepatitis B serology screening among HIV-infected patients in a resource-limited setting: an issue to improve for long-term HIV care
Presented by Sasisopin Kiertiburanakul, Thailand
S. Kiertiburanakul, D. Chotiprasitsakul, K. Atamasirikul, S. Sungkanuparph
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Department of Medicine, Bangkok, Thailand

Rapporteur report

Track B report by Jose ARRIBAS

WEPDB2 Viral Hepatitis Co-Infection. Oral Poster Discussions

This session included a discussion of 6 interesting posters presentations related to liver disease in HIV-infected patients. The most important take home messages were:

Initial response to peg interferon alfa 2a plus ribavirin in HIV/HCV coinfected patients with persistently normal ALT levels is comparable to those with elevated ALT levels in a small clinical trial (WEPDB201)
As have been seen in other studies, fibroscan might be a good method to predict the presence of esophageal varices in patients with end-stage liver disease (WEPDB202)
HCV genotype 3 predominates in some Russian regions (Krasnoyarsk region). This finding has implications for treatment of coinfected patients (WEPDB203)
In HIV/HBVcoinfected patients treated with HAART, lamivudine resistance is less frequent than in immunocompetent patients but when occurred, was associated with an accelerated course of liver disease, with faster progression to cirrhosis, liver insufficiency and HCC (WEPDB204)
The prevalence of HIV/HBV coinfection in Bostwana is around 5% with an apparent increase in recent years (WEPDB205)
In Bangkok, a study has shown a late and low compliance with hepatitis B serology screening among HIV infected patients (WEPDB206)